Screening for Subclinical Enthesitis in Inflammatory Disease

Abstract

Subclinical enthesitis, an early marker of inflammatory involvement in spondyloarthropathies and related disorders, often precedes overt clinical symptoms. Early detection through sensitive screening approaches is crucial for timely intervention, improved outcomes, and prevention of irreversible structural damage. This review synthesizes recent evidence on the burden, pathophysiology, risk factors, and diagnostic modalities for subclinical enthesitis in inflammatory diseases, emphasizing guideline-based recommendations and emerging advances for effective screening and management.

Introduction

Enthesitis the inflammation at sites where tendons, ligaments, or joint capsules attach to bone is a cardinal feature of spondyloarthropathies (SpA), psoriatic arthritis (PsA), and other inflammatory conditions. Subclinical enthesitis refers to inflammatory changes at the entheses not yet evident on physical examination, but detectable via imaging or biomarker analysis. Early identification of subclinical enthesitis is of paramount importance as it may strongly predict future joint damage, functional impairment, and progression to clinically overt disease. This review critically appraises the current understanding and clinical implications of screening for subclinical enthesitis in patients with inflammatory diseases, with a focus on evidence-based strategies and recent guideline updates.

Epidemiology / Disease Burden

Subclinical enthesitis is prevalent among individuals with SpA, PsA, and inflammatory bowel disease-associated arthritis, with studies reporting sonographic enthesitis in up to 60% of patients with early SpA and approximately 40% in psoriasis without clinical arthritis. The true burden is likely underestimated due to limited sensitivity of clinical examination. Subclinical enthesitis is also increasingly recognized in other chronic inflammatory conditions, highlighting its importance as an early disease marker. Notably, the presence of subclinical enthesitis correlates with more severe disease phenotypes, increased risk of structural damage, and reduced quality of life, further substantiating the need for systematic screening in at-risk populations.

Pathophysiology

Entheses are unique anatomical sites subjected to mechanical stress and possess specialized fibrocartilaginous structure. In genetically susceptible individuals, such as those with HLA-B27 positivity, biomechanical microtrauma may incite aberrant innate and adaptive immune responses. Cytokines such as TNF-α, IL-17, and IL-23 play pivotal roles, promoting local inflammation and pathological bone remodeling. Recent studies highlight the role of resident enthesis immune cells and the gut–enthesis axis in disease perpetuation. Subclinical enthesitis represents the earliest detectable phase of this pathophysiological continuum, preceding synovitis and joint destruction.

Risk Factors

Key risk factors for subclinical enthesitis include a personal or family history of SpA or psoriasis, HLA-B27 positivity, male sex, younger age at disease onset, high mechanical stress (e.g., athletes, manual laborers), and comorbidities such as obesity or metabolic syndrome. Certain medications, infections, and environmental exposures may modulate risk by influencing immune or mechanical pathways. Identification of at-risk individuals is fundamental for targeted screening and early intervention.

Clinical Features

By definition, subclinical enthesitis is asymptomatic; patients lack overt tenderness or swelling at enthesis sites. However, subtle symptoms such as morning stiffness, mild discomfort during activity, or vague regional pain may be reported. Subclinical enthesitis is often discovered incidentally during imaging for related conditions. The absence of clinical findings underscores the need for objective, sensitive screening tools to identify early inflammatory changes before symptom onset and irreversible damage.

Diagnosis

Diagnosis of subclinical enthesitis relies primarily on advanced imaging techniques. Musculoskeletal ultrasound (MSUS) is the preferred modality, capable of detecting structural changes (e.g., thickening, erosions) and active inflammation (e.g., power Doppler signal) with high sensitivity. MRI offers excellent resolution for deep-seated entheses and can reveal bone marrow edema indicative of early involvement. Whole-body MRI and high-resolution ultrasound scoring systems (e.g., MASEI, GUESS, OMERACT definitions) have improved reliability and reproducibility. Laboratory biomarkers such as C-reactive protein and calprotectin lack specificity for enthesitis but may provide supportive information. A comprehensive diagnostic approach integrates clinical context, imaging, and, where available, biomarker data.

Treatment & Management

Management of subclinical enthesitis focuses on controlling underlying inflammatory activity and preventing progression to overt disease. Nonsteroidal anti-inflammatory drugs (NSAIDs) may offer symptomatic relief, although their role in subclinical, asymptomatic cases is limited. Conventional disease-modifying antirheumatic drugs (DMARDs) have limited efficacy for enthesitis, particularly in SpA. Biologic agents targeting TNF-α, IL-17, and IL-23 demonstrate significant efficacy in reducing enthesitis burden, as evidenced in multiple randomized controlled trials. Early initiation of biologic therapy in patients with subclinical enthesitis and additional risk factors may improve long-term outcomes. Tailored exercise regimens and mechanical load management are recommended adjuncts.

Recent Advances / Emerging Therapies

Recent advances include the refinement of ultrasound and MRI protocols for early enthesitis detection, development of composite scoring systems, and artificial intelligence-assisted image interpretation. Novel therapeutic agents, such as JAK inhibitors and next-generation anti-cytokine biologics, show promise in enthesitis modulation. Ongoing trials are evaluating the utility of targeted preventive therapy in high-risk individuals identified by subclinical imaging findings, aiming to delay or prevent progression to clinically apparent arthritis.

Guideline Recommendations

Current international guidelines (e.g., ASAS, EULAR) recommend the use of imaging to supplement clinical assessment in patients with suggestive symptoms or at high risk for SpA or PsA. Routine screening for subclinical enthesitis is not yet universally endorsed due to resource and cost considerations. However, guidelines recognize the prognostic value of early enthesitis detection and support screening in research settings or select clinical scenarios, such as high-risk populations or individuals with persistent unexplained musculoskeletal symptoms. Ongoing updates to guidelines may expand recommendations as evidence for preventive strategies grows.

Conclusion

Subclinical enthesitis is an underrecognized but clinically significant entity in the spectrum of inflammatory diseases. Advanced imaging techniques have enabled earlier detection, offering the potential for timely intervention and improved long-term outcomes. Risk stratification, integration of imaging into screening protocols, and evolving therapeutic strategies are poised to enhance the management of patients at risk for enthesitis-related morbidity. Continued research and guideline evolution will refine best practices for early identification and intervention in subclinical enthesitis.